Published in Int J Radiat Oncol Biol Phys on March 01, 2010
High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol (2013) 1.34
2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver (2015) 1.23
Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol (2011) 1.22
Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma. PLoS One (2013) 1.22
Hypofractionated carbon ion therapy delivered with scanned ion beams for patients with hepatocellular carcinoma - feasibility and clinical response. Radiat Oncol (2013) 1.19
2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol (2015) 1.14
Gastrointestinal radiation injury: symptoms, risk factors and mechanisms. World J Gastroenterol (2013) 1.06
Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol (2014) 1.06
Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters. Radiat Oncol (2013) 1.04
Prediction of liver function by using magnetic resonance-based portal venous perfusion imaging. Int J Radiat Oncol Biol Phys (2012) 0.99
Stereotactic radiation therapy for liver metastases: factors affecting local control and survival. Radiat Oncol (2015) 0.99
Radiation treatment with volumetric modulated arc therapy of hepatocellular carcinoma patients. Early clinical outcome and toxicity profile from a retrospective analysis of 138 patients. Radiat Oncol (2012) 0.99
Determination of the α/β ratio for the normal liver on the basis of radiation-induced hepatic toxicities in patients with hepatocellular carcinoma. Radiat Oncol (2013) 0.98
A case of emphysematous hepatitis with spontaneous pneumoperitoneum in a patient with hilar cholangiocarcinoma. Korean J Hepatol (2012) 0.97
Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol (2012) 0.95
Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol (2014) 0.94
Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review. Radiat Oncol (2012) 0.93
The efficacy of stereotactic body radiation therapy on huge hepatocellular carcinoma unsuitable for other local modalities. Radiat Oncol (2014) 0.92
Stem cell therapies for the treatment of radiation-induced normal tissue side effects. Antioxid Redox Signal (2014) 0.90
Feasibility of stereotactic body radiation therapy with volumetric modulated arc therapy and high intensity photon beams for hepatocellular carcinoma patients. Radiat Oncol (2014) 0.89
Mitigation of Lethal Radiation Syndrome in Mice by Intramuscular Injection of 3D Cultured Adherent Human Placental Stromal Cells. PLoS One (2013) 0.88
Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Int J Cancer (2014) 0.88
Hepatocyte growth factor gene-modified adipose-derived mesenchymal stem cells ameliorate radiation induced liver damage in a rat model. PLoS One (2014) 0.87
Application of Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular Carcinoma. Liver Cancer (2012) 0.87
Radiotherapy with volumetric modulated arc therapy for hepatocellular carcinoma patients ineligible for surgery or ablative treatments. Strahlenther Onkol (2013) 0.87
What is the appropriate size criterion for proton radiotherapy for hepatocellular carcinoma? A dosimetric comparison of spot-scanning proton therapy versus intensity-modulated radiation therapy. Radiat Oncol (2013) 0.85
Estimating functional liver reserve following hepatic irradiation: adaptive normal tissue response models. Radiother Oncol (2014) 0.84
Stereotactic body radiotherapy treatment of extracranial metastases. Nat Rev Clin Oncol (2012) 0.84
Bilateral kidney preservation by volumetric-modulated arc therapy (RapidArc) compared to conventional radiation therapy (3D-CRT) in pancreatic and bile duct malignancies. Radiat Oncol (2011) 0.84
New techniques for assessing response after hypofractionated radiotherapy for lung cancer. J Thorac Dis (2014) 0.83
A comparison of liver protection among 3-D conformal radiotherapy, intensity-modulated radiotherapy and RapidArc for hepatocellular carcinoma. Radiat Oncol (2014) 0.83
The impact of beam angle configuration of intensity-modulated radiotherapy in the hepatocellular carcinoma. Radiat Oncol J (2012) 0.81
Hepatic fat accumulation and regulation of FAT/CD36: an effect of hepatic irradiation. Int J Clin Exp Pathol (2014) 0.81
Dosimetric comparison of carbon ion radiotherapy and stereotactic body radiotherapy with photon beams for the treatment of hepatocellular carcinoma. Radiat Oncol (2015) 0.80
The response of thrombosis in the portal vein or hepatic vein in hepatocellular carcinoma to radiation therapy. Radiat Oncol J (2016) 0.79
Efficacy and Safety of Intensity-Modulated Radiotherapy Following Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma. Medicine (Baltimore) (2016) 0.79
Reducing the probability of radiation-induced hepatic toxicity by changing the treatment modality from helical tomotherapy to fixed-beam intensity-modulated radiotherapy. Oncotarget (2015) 0.79
Double-arc volumetric modulated therapy improves dose distribution compared to static gantry IMRT and 3D conformal radiotherapy for adjuvant therapy of gastric cancer. Radiat Oncol (2015) 0.79
A feasibility study evaluating the relationship between dose and focal liver reaction in stereotactic ablative radiotherapy for liver cancer based on intensity change of Gd-EOB-DTPA-enhanced magnetic resonance images. Radiat Oncol J (2016) 0.78
High-dose hypofractionated X-ray radiotherapy for hepatocellular carcinoma: Tumor responses and toxicities. Oncol Lett (2013) 0.78
Activation of the JNK-c-Jun pathway in response to irradiation facilitates Fas ligand secretion in hepatoma cells and increases hepatocyte injury. J Exp Clin Cancer Res (2016) 0.78
Distribution of functional liver volume in hepatocellular carcinoma patients with portal vein tumor thrombus in the 1st branch and main trunk using single photon emission computed tomography-application to radiation therapy. Cancers (Basel) (2011) 0.77
Dosimetric differences among volumetric modulated arc radiotherapy (RapidArc) plans based on different target volumes in radiotherapy of hepatocellular carcinoma. J Radiat Res (2012) 0.77
Threshold doses and prediction of visually apparent liver dysfunction after stereotactic body radiation therapy in cirrhotic and normal livers using magnetic resonance imaging. J Radiat Res (2016) 0.77
Technical advances in external radiotherapy for hepatocellular carcinoma. World J Gastroenterol (2016) 0.77
Radiation-Induced Liver Injury in Three-Dimensional Conformal Radiation Therapy (3D-CRT) for Postoperative or Locoregional Recurrent Gastric Cancer: Risk Factors and Dose Limitations. PLoS One (2015) 0.76
Identification of Biologically Effective Dose-Volumetric Parameters That Predict Radiation-Induced Hepatic Toxicity in Patients Treated With Helical Tomotherapy for Unresectable Locally Advanced Hepatocellular Carcinoma. Medicine (Baltimore) (2015) 0.76
Low Hepatic Toxicity in Primary and Metastatic Liver Cancers after Stereotactic Ablative Radiotherapy Using 3 Fractions. J Korean Med Sci (2015) 0.76
Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model. Oncotarget (2016) 0.75
Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. Radiat Oncol J (2016) 0.75
Early experience of helical tomotherapy for hepatobiliary radiotherapy. Case Reports Hepatol (2011) 0.75
Outcomes and Predictors of Toxicity after Selective Internal Radiation Therapy Using Yttrium-90 Resin Microspheres for Unresectable Hepatocellular Carcinoma. Front Oncol (2015) 0.75
Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma. BMC Cancer (2016) 0.75
Liver regeneration and energetic changes in rats following hepatic radiation therapy and hepatocyte transplantation by ³¹P MRSI. Liver Int (2014) 0.75
A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases. Ann Surg Oncol (2015) 0.75
Optimal Selection of Radiotherapy as Part of a Multimodal Approach for Hepatocellular Carcinoma. Liver Cancer (2016) 0.75
Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma. Radiat Oncol (2016) 0.75
Radiotherapy for gastric lymphoma: a planning study of 3D conformal radiotherapy, the half-beam method, and intensity-modulated radiotherapy. J Radiat Res (2014) 0.75
Stereotactic ablative radiotherapy for oligometastatic disease in liver. Biomed Res Int (2014) 0.75
Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm. BMC Cancer (2016) 0.75
Treatment outcome of hepatic re-irradiation in patients with hepatocellular carcinoma. Radiat Oncol J (2015) 0.75
PET/CT-guided treatment planning for paediatric cancer patients: a simulation study of proton and conventional photon therapy. Br J Radiol (2014) 0.75
Re-Irradiation of Hepatocellular Carcinoma: Clinical Applicability of Deformable Image Registration. Yonsei Med J (2016) 0.75
Combination of Photon and Carbon Ion Irradiation with Targeted Therapy Substances Temsirolimus and Gemcitabine in Hepatocellular Carcinoma Cell Lines. Front Oncol (2017) 0.75
Validation of the liver mean dose in terms of the biological effective dose for the prevention of radiation-induced liver damage. Rep Pract Oncol Radiother (2017) 0.75
Clinical parameters for predicting radiation-induced liver disease after intrahepatic reirradiation for hepatocellular carcinoma. Radiat Oncol (2016) 0.75
Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model. EJNMMI Res (2017) 0.75
Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results. Oncotarget (2017) 0.75
Dose to organ at risk and dose prescription in liver SBRT. Rep Pract Oncol Radiother (2017) 0.75
A Review of Non-operative Treatments for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombus. J Clin Transl Hepatol (2017) 0.75
Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma. Radiat Oncol (2017) 0.75
Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys (1991) 13.16
Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys (2008) 5.03
Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys (2002) 3.64
Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys (1995) 3.20
Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol (2008) 3.02
Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol (2009) 2.78
A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys (2005) 2.41
Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2003) 2.34
Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol (2006) 2.16
RADIATION HEPATITIS. Am J Roentgenol Radium Ther Nucl Med (1965) 2.14
Colorectal metastasis (liver and lung). Surg Clin North Am (2002) 2.09
Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. Int J Radiat Oncol Biol Phys (2006) 2.00
Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys (2006) 1.85
Partial volume tolerance of the liver to radiation. Semin Radiat Oncol (2005) 1.85
Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2007) 1.77
Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol (2006) 1.72
Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. Int J Radiat Oncol Biol Phys (2002) 1.60
Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys (2003) 1.56
The reproducibility of organ position using active breathing control (ABC) during liver radiotherapy. Int J Radiat Oncol Biol Phys (2001) 1.56
Analysis of clinical complication data for radiation hepatitis using a parallel architecture model. Int J Radiat Oncol Biol Phys (1995) 1.54
Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.54
Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol (2006) 1.53
Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys (2004) 1.38
Intrafractional tumor motion: lung and liver. Semin Radiat Oncol (2004) 1.37
Image-guided radiotherapy for liver cancer using respiratory-correlated computed tomography and cone-beam computed tomography. Int J Radiat Oncol Biol Phys (2008) 1.29
Transforming growth factor-beta 1 expression in irradiated liver. Radiat Res (1990) 1.27
Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors. Int J Radiat Oncol Biol Phys (2003) 1.27
Use of principal component analysis to evaluate the partial organ tolerance of normal tissues to radiation. Int J Radiat Oncol Biol Phys (2005) 1.11
Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys (1993) 1.11
Inclusion of organ deformation in dose calculations. Med Phys (2003) 1.09
High-dose localized radiation therapy for treatment of hepatic malignant tumors: CT findings and their relation to radiation hepatitis. AJR Am J Roentgenol (1995) 1.03
Alterations in normal liver doses due to organ motion. Int J Radiat Oncol Biol Phys (2003) 1.00
Inclusion of biological factors in parallel-architecture normal-tissue complication probability model for radiation-induced liver disease. Int J Radiat Oncol Biol Phys (2005) 0.97
Extrahepatic portal vein occlusion without recurrence after pancreaticoduodenectomy and intraoperative radiation therapy. Int J Radiat Oncol Biol Phys (2005) 0.97
Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis. Strahlenther Onkol (2006) 0.96
Estimate of radiobiologic parameters from clinical data for biologically based treatment planning for liver irradiation. Int J Radiat Oncol Biol Phys (2008) 0.91
Influence of prognostic groupings and treatment results in the management of unresectable hepatoma: experience with Cisplatinum-based chemoradiotherapy in 76 patients. Int J Radiat Oncol Biol Phys (1997) 0.88
Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol (2004) 0.86
Local stem cell depletion model for radiation myelitis. Int J Radiat Oncol Biol Phys (1988) 0.84
Accelerated fractionation radiation therapy for liver metastases: selection of an optimal patient population for the evaluation of late hepatic injury in RTOG studies. Int J Radiat Oncol Biol Phys (1990) 0.80
Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol (2009) 4.59
Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys (2010) 4.33
Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol (2013) 3.76
Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol (2013) 3.70
Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys (2002) 3.64
Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys (2006) 3.40
Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2002) 3.39
High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys (2005) 3.32
Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol (2008) 3.02
Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol (2009) 3.00
Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys (2010) 2.94
Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol (2007) 2.80
Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol (2009) 2.78
Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol (2009) 2.74
Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys (2010) 2.69
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol (2012) 2.47
How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys (2003) 2.46
Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys (2003) 2.41
A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys (2005) 2.41
Change in diffusion weighted MRI during liver cancer radiotherapy: preliminary observations. Acta Oncol (2009) 2.33
Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys (2010) 2.32
Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol (2005) 2.20
Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol (2004) 2.15
Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys (2009) 2.14
Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys (2004) 2.00
Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: patterns of failure. Oral Oncol (2012) 1.98
Accelerator beam data commissioning equipment and procedures: report of the TG-106 of the Therapy Physics Committee of the AAPM. Med Phys (2008) 1.89
Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer (2011) 1.87
Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys (2012) 1.85
Partial volume tolerance of the liver to radiation. Semin Radiat Oncol (2005) 1.85
Assessment of a model-based deformable image registration approach for radiation therapy planning. Int J Radiat Oncol Biol Phys (2007) 1.75
Radiation-associated kidney injury. Int J Radiat Oncol Biol Phys (2010) 1.74
Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer (2006) 1.71
Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys (2012) 1.70
Prospective comparison of breast pain in patients participating in a randomized trial of breast-conserving surgery and tamoxifen with or without radiotherapy. Int J Radiat Oncol Biol Phys (2003) 1.67
Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. Int J Radiat Oncol Biol Phys (2009) 1.64
Comparison of in vitro and in vivo alpha/beta ratios for prostate cancer. Phys Med Biol (2004) 1.63
Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys (2012) 1.55
Retrospective analysis of prostate cancer patients with implanted gold markers using off-line and adaptive therapy protocols. Int J Radiat Oncol Biol Phys (2005) 1.55
A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol (2007) 1.55
The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys (2006) 1.52
Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys (2005) 1.49
The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol (2007) 1.49
Predicting radiotherapy-induced cardiac perfusion defects. Med Phys (2005) 1.47
Quantifying interfraction and intrafraction tumor motion in lung stereotactic body radiotherapy using respiration-correlated cone beam computed tomography. Int J Radiat Oncol Biol Phys (2009) 1.47
Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol (2011) 1.46
Impact of prolonged fraction delivery times on tumor control: a note of caution for intensity-modulated radiation therapy (IMRT). Int J Radiat Oncol Biol Phys (2003) 1.45
Improving normal tissue complication probability models: the need to adopt a "data-pooling" culture. Int J Radiat Oncol Biol Phys (2010) 1.44
Response to letter to the editor with reference to article "Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: patterns of failure". Oral Oncol (2013) 1.40
Self-consistent tumor control probability and normal tissue complication probability models based on generalized EUD. Med Phys (2007) 1.40
Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. Int J Radiat Oncol Biol Phys (2003) 1.39
CT-based definition of thoracic lymph node stations: an atlas from the University of Michigan. Int J Radiat Oncol Biol Phys (2005) 1.38
Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol (2012) 1.38
Dose reconstruction in deforming lung anatomy: dose grid size effects and clinical implications. Med Phys (2005) 1.36
Tools for consensus analysis of experts' contours for radiotherapy structure definitions. Radiother Oncol (2010) 1.36
Chemo-IMRT of oropharyngeal cancer aiming to reduce dysphagia: swallowing organs late complication probabilities and dosimetric correlates. Int J Radiat Oncol Biol Phys (2011) 1.33
Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinoma. Int J Radiat Oncol Biol Phys (2006) 1.32
Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. World J Surg (2003) 1.28
Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin (2009) 1.28
Renin-Angiotensin system suppression mitigates experimental radiation pneumonitis. Int J Radiat Oncol Biol Phys (2009) 1.25
A methodology for using SPECT to reduce intensity-modulated radiation therapy (IMRT) dose to functioning lung. Int J Radiat Oncol Biol Phys (2006) 1.24
Image-guided radiotherapy: has it influenced patient outcomes? Semin Radiat Oncol (2012) 1.23
Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol (2011) 1.22
Evaluation of a commercial biologically based IMRT treatment planning system. Med Phys (2008) 1.22
Parotid gland function after radiotherapy: the combined michigan and utrecht experience. Int J Radiat Oncol Biol Phys (2010) 1.21
Methodological issues in radiation dose-volume outcome analyses: summary of a joint AAPM/NIH workshop. Med Phys (2002) 1.20
Guest editor's introduction to QUANTEC: a users guide. Int J Radiat Oncol Biol Phys (2010) 1.20
A region growing method for tumor volume segmentation on PET images for rectal and anal cancer patients. Med Phys (2009) 1.19
Simultaneous integrated boost for breast cancer using IMRT: a radiobiological and treatment planning study. Int J Radiat Oncol Biol Phys (2004) 1.19
Commissioning and clinical implementation of a mega-voltage cone beam CT system for treatment localization. Med Phys (2007) 1.19
Reproducibility of liver position using active breathing coordinator for liver cancer radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.18
The role of local therapy in the management of lung and liver oligometastases. Nat Rev Clin Oncol (2011) 1.17
Adapting population liver motion models for individualized online image-guided therapy. Conf Proc IEEE Eng Med Biol Soc (2008) 1.16
A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer (2013) 1.16
Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys (2008) 1.14
Direct aperture optimization-based intensity-modulated radiotherapy for whole breast irradiation. Int J Radiat Oncol Biol Phys (2007) 1.14
How extensive of a 4D dataset is needed to estimate cumulative dose distribution plan evaluation metrics in conformal lung therapy? Med Phys (2007) 1.13
Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radiother Oncol (2012) 1.12
A dose-volume-based tool for evaluating and ranking IMRT treatment plans. J Appl Clin Med Phys (2004) 1.12
Inter- and intrafraction variability in liver position in non-breath-hold stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys (2009) 1.11
Use of principal component analysis to evaluate the partial organ tolerance of normal tissues to radiation. Int J Radiat Oncol Biol Phys (2005) 1.11
Radiotherapy for hepatocellular carcinoma: an overview. Ann Surg Oncol (2008) 1.10
Clinical implementation of intensity-modulated arc therapy. Int J Radiat Oncol Biol Phys (2002) 1.10
Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer. Int J Radiat Oncol Biol Phys (2012) 1.10
Physical models and simpler dosimetric descriptors of radiation late toxicity. Semin Radiat Oncol (2007) 1.10
Interfraction and respiratory organ motion during conformal radiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys (2009) 1.09
Quality assurance for image-guided radiation therapy utilizing CT-based technologies: a report of the AAPM TG-179. Med Phys (2012) 1.09